NewsMV
In focus for IOVA: an August 2026 corporate overview filed with the SEC shows Iovance Biotherapeutics generated approximately $99 million in second-quarter revenue, a print the company described as more than 10% above its own 2Q26 guidance.
The figure reflects roughly 66% year-over-year quarterly revenue growth.
Cash, cash equivalents, short-term investments, and restricted cash totaled approximately $304 million as of June 30, 2026, with runway projected into the second half of 2028.
The numbers behind the beat Gross margin from cost of sales came in above 95%, excluding depreciation and amortization.
Keep reading